Long-lived plasma cells, which produce autoantibodies in diseases such as systemic lupus erythematosus (SLE), are an as yet unexplored therapeutic target in such antibody-mediated disorders.

The study by the Sajadi and Lewis teams examined the contribution of long-lived plasma cells in the bone marrow to anti-spike antibodies after COVID-19 infection. The study studied 20 individuals ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the induction of high-affinity antibodies derived from GCs and produced by ...

Plasma cells (PCs) are the terminal differentiation stage of activated B cells and serve as crucial effector cells in humoral immunity. While PCs have ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma cells ...

Finally, targeting BCMA with antibody drug conjugates (ADCs ... BMS is targeting the warhead directly to plasma cells to avoid the non-specific toxicity observed with systemic administration ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

These results were similar to those of the control antibody. Plasma cells at the end stage of B cell differentiation are organized using Beacon ®, and memory B cells with antibodies expressed on ...

It’s of particular interest to several research groups and companies currently developing plasma therapies, whereby antibody-containing blood plasma is extracted from recovered patients and ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...